Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 24 Jan 2023, 15:07.
Christopher B. Ehrlich - 20 Jan 2023 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Role
- Director
- Signature
- /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
- Issuer symbol
- N/A
- Transactions as of
- 20 Jan 2023
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 24 Jan 2023, 15:07:18 UTC
- Previous filing
- 06 Oct 2022
- Next filing
- 22 Jun 2023
- SEC
- View on sec.gov
Key filing fact
Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 24 Jan 2023.
Change
- Previous filing in this sequence was filed on 06 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
EFTR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,938
- Change %
- Price
- $0.000000
- Shares after
- 35,938
- Date
- 20 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,938
- Exercise price
- $0.4688
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on January 20, 2023, subject to the Reporting Person's continued service with the Issuer through each vesting date. |